Hummingbird and Synaffix in $150m ADC deal
Rational antibody design specialist Hummingbird Bioscience has licenced a cancer target and the modular ADC technology of Dutch Synaffix BV.
Ethris inks 15m deal with Indian Ciplas
Cipla EU Ltd is going to make an equity investment of 15m in Ethris GmbH, a specialist for respiratory delivery of therapeutic mRNAs.
First hints for leukopenia diagnostic in MS
Scientists from the University of Basel and the University Hospital Basel have found that two bacterial species may indicate multiple sclerosis-associated lymphopenia.
Numares AG cashes in 20m from EIB
The European Investment Bank (EIB) is going to support the AI-platform of NMR/metabolomics diagnostics company Numares AG to improve disease prediction.
Amgen wins race of top `22 deals with $26bn for Horizon thx
According to Bloomberg, the US biotechnology giant Amgen plans to buy Horizon Therapeutics at a valuation of about $26bn. Overall, the deal corresponds to an enterprise value including debt of $28.3bn. This would be the largest acquisition in the company’s history.
European Commission calls for reversal of Illumina’s $7bn Grail merger
The European Commission has now recommended concrete steps that, while not yet final, would require Illumina to "swiftly" reverse its controversial $7.1bn acquisition of Grail.
BioNTech and Ryvu Therapeutics enter into global collaboration
Renewed focus on cancer: COVID-19 vaccine company BioNTech SE (Nasdaq: BNTX) and Ryvu Therapeutics S.A., located in Krakow (Warsaw Stock Exchange: RVU), a Polish clinical-stage cancer therapeutics development company, announced that the companies have entered into a research collaboration for several multi-target immunotherapy programmes, as well as an exclusive licensing agreement for Ryvu’s STING agonist portfolio as stand-alone small molecules.
Amsterdam Neogene Therapeutics aquired by AstraZeneca
AstraZeneca announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company spezialised in next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer. The acquisition delivers an initial payment of $200m on deal closing, and a further up to $120m in both contingent milestones-based and non-contingent consideration.
British AI provider raises $33m in Series A financing
London-based computer vision specialist V7 Ltd has baged $33m in Series A financing co-led by AI-focused Radical Ventures and Temasek.
Growing investor interest in biotechnology
Latest investment trends were presented by BIOTECH Insight at the start of the German Equity Forum